What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence

Current Opinion in Urology

Volumn 28, Issue 6, 2018, Pages 570-576

  Abufaraj, Mohammad ^a,b   Mostafid, Hugh ^c   Shariat, Shahrokh F ^a,d,e,f   Babjuk, Marek ^c,g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JORDAN UNIVERSITY HOSPITAL   (Jordan)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d Wilhelminenspital   (Austria)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Bacillus Calmette Gu rin; Bacillus Calmette Gu rin shortage; gemcitabine; intravesical therapy; mitomycin C; nonmuscle invasive bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE;

BLADDER; BLADDER TUMOR; CLINICAL DECISION MAKING; CYSTECTOMY; DISEASE EXACERBATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; MORTALITY; PATHOLOGY; PROCEDURES; SUPPLY AND DISTRIBUTION; SURGERY; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; CLINICAL DECISION-MAKING; CYSTECTOMY; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 85064210938     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000544     Document Type: Review

References (53)

1. Babjuk M, Bö hle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update. Eur Urol 2017; 71:447-461.
2. Rieken M, Shariat SF, Kluth L, et al. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol Oncol Semin Orig Investig 2018; 36:8e17-8e24.
3. Boehm BE, Cornell JE, Wang H, et al. Efficacy of bacillus Calmette-Gué rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 2017; 198:503-510.
4. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gué rin for nonmuscleinvasive bladder cancer. Eur Urol 2009; 56:247-256.
5. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970.
6. Bö hle A, Bock P. Intravesical Bacille Calmette-Gué rin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; 63:682-686.
7. Sengiku A, Ito M, Miyazaki Y, et al. A prospective comparative study of intravesical Bacillus Calmette-Gué rin therapy with the Tokyo or Connaught Strain for nonmuscle invasive bladder cancer. J Urol 2013; 190:50-54.
8. Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of Bacille Calmette-Gué rin. Eur Urol 2015; 67:359-360.
9. Sanofi Shuts Down Bladder Cancer Drug Production: Inevitable Drug Shortage To Harm Patients n.d. https://www.forbes.com/sites/benjamindavies/ 2016/11/17/sanofi-shuts-down-bladder-cancer-drug-production-inevitabledrug-shortage-to-harm-patients/#1e4d4cb8c132. [Accessed 20 May 2018]
10. Sanofi discontinuing bladder cancer drug TheraCys after years of production issues j FiercePharma n.d. https://www.fiercepharma.com/manufacturing/ sanofi-discontinuing-bladder-cancer-drug-teracys-after-years-production-issues. [Accessed 20 May 2018]
11. Messing EM. The BCG shortage. Bladder Cancer 2017; 3:227-228.
12. Davies BJ, Hwang TJ, Kesselheim AS. Ensuring access to injectable generic drugs: the case of intravesical BCG for bladder cancer. N Engl J Med 2017; 376:1401-1403.
13. Hofbauer SL, Shariat SF, Chade DC, et al. The Moreau strain of Bacillus Calmette-Guerin (BCG) for high-risk non-muscle invasive bladder cancer: an alternative during worldwide BCG shortage? Urol Int 2016; 96:46-50.
14. Rentsch CA, Birkhä user FD, Biot C, et al. Bacillus Calmette-Gué rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 2014; 66:677-688.
15. Witjes JA, Dalbagni G, Karnes RJ, et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig 2016; 34:484.e19-484.e25.
16. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116:180-183.
17. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance Bacillus Calmette-Gué rin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: onethird dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; 63:462-472.
18. Herr HW, Dalbagni G, Donat SM. Bacillus Calmette-Gué rin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 2011; 60:32-36.
19. Kamat AM, Flaig TW, Grossman HB, et al. Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 2015; 12:225-235.
20. Martínez-Pin eiro JA,Martínez-Pin eiro L, Solsona E, et al. Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression ofT1G3 and Tis bladder tumors than the standard dose?Results of a prospective randomized trial. J Urol 2005; 174:1242-1247.
21. Inman BA. Re: Has a 3-fold decreased dose of Bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2006; 175:1960-1961.
22. Ojea A, Nogueira JL, Solsona E, et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose Bacillus Calmette-Guerin (27 mg) versus very low-dose Bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007; 52:1398-1406.
23. Biot C, Rentsch CA, Gsponer JR, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci TranslMed 2012; 4:137ra72.
24. Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus Bacillus Calmette-Gué rin for adjuvant treatment of patients with intermediate-and highrisk non-muscle-invasive bladder cancer. Eur Urol 2016; 69:1046-1052.
25. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008; 53:709-719.
26. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003; 21:4270-4276.
27. van der Heijden A, Kiemeney L, Gofrit O, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46:65-72.
28. Lammers RJ,Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscle-invasive bladder cancer: a systematic review. Eur Urol 2011; 60:81-93.
29. Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for nonmuscle-invasive bladder cancer (NMIBC). BJU Int 2011; 107:912-918.
30. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7:43-51.
31. di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin c versus passive transport mitomycin c for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003; 170:777-782.
32. Jung JH, Gudeloglu A, Kiziloz H, et al. Intravesical electromotive drug administration for nonmuscle invasive bladder cancer. Cochrane Database Syst Rev 2017; 9:CD011864.
33. Prasanna T, Craft P, Balasingam G, et al. Intravesical gemcitabine versus intravesical Bacillus Calmette-Gué rin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity. Front Oncol 2017; 7:260.
34. Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for nonmuscle invasive bladder cancer (NMIBC): a systematic review. BJU Int 2012; 109:496-505.
35. Di Lorenzo G, Perdona S, Damiano R, et al. Gemcitabine versus Bacille Calmette-Gué rin after initial Bacille Calmette-Gué rin failure in nonmuscleinvasive bladder cancer. Cancer 2010; 116:1893-1900.
36. Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for nonmuscle invasive bladder cancer. Cochrane Database Syst Rev 2012; 1:CD009294.
37. Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010; 28:543-548.
38. Porena M, Del Zingaro M, Lazzeri M, et al. Bacillus Calmette-Gué rin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 2010; 84:23-27.
39. Gardmark T, Carringer M, Beckman E, Malmström PU; Members of the Intravesical Gemcitabine Study Group. Randomized Phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology 2005; 66:527-530.
40. Bö hle A, Leyh H, Frei C, et al. Single postoperative instillation of gemcitabine in patients with nonmuscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase iii multicentre study. Eur Urol 2009; 56:495-503.
41. Bartoletti R, Cai T,Gacci M, et al., TUR (Toscana Urologia) Group. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 2005; 66:726-731.
42. Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999; 86:1818-1826.
43. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscleinvasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 2008; 53:45-52.
44. Sharma P, Zargar-Shoshtari K, Sexton WJ. Valrubicin in refractory nonmuscle invasive bladder cancer. Expert Rev Anticancer Ther 2015; 15:1379-1387.
45. Chen J, Yao Z, Qiu S, et al. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery. Cardiovasc Intervent Radiol 2013; 36:1521-1526.
46. Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 2017; 197:1189-1199.
47. Shepherd AR, Shepherd E, Brook NR. Intravesical Bacillus Calmette-Gué rin with interferon-alpha versus intravesical Bacillus Calmette-Gué rin for treating nonmuscle-invasive bladder cancer. Cochrane Database Syst Rev 2017; 3:CD012112.
48. Marttila T, Jä rvinen R, Liukkonen T, et al. Intravesical Bacillus Calmette-Gué rin versus combination of epirubicin and interferon-a2a in reducing recurrence of non-muscle-invasive bladder carcinoma: FinnBladder-6 study. Eur Urol 2016; 70:341-347.
49. D'Andrea D, Abufaraj M, Susani M, et al. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool. Urol Oncol 2018; 36:239.e1-239.e7.
50. Sylvester R, Vandermeijden A, Witjes J, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; 174:86-91.
51. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422.
52. Moschini M, Sharma V, Dell'oglio P, et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int 2016; 117:604-610.
53. Liljenquist D, Bai G, Anderson GF. Addressing generic-drug market failures: the case for establishing a nonprofit manufacturer. N Engl J Med 2018; 378:1857-1859.